ANI Pharmaceuticals (ANIP) News
NASDAQ: ANIPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
68.55-0.58 (-0.84%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANIP news summary
We found 19 recent headlines mentioning ANI Pharmaceuticals (ANIP): 2 in the past week and 10 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, ANIP is down 0.84% at $68.55. The most recent story, "ANI Pharmaceuticals to Present at Upcoming December Investor Conference", was published by GlobeNewswire on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest ANI Pharmaceuticals headlines
- ANI Pharmaceuticals to Present at Upcoming December Investor ConferencePRINCETON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with…GlobeNewswire
- ANI Pharmaceuticals, Inc. Details Offer to Acquire Egetis Therapeutics for SEK 5.6BANI Pharmaceuticals, Inc. has announced a public cash tender offer to acquire Egetis Therapeutics, a Swedish public limited liability company, for SEK 11.25 per share. The total offer value is SEK…Nasdaq
- ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue EstimatesANI (ANIP) delivered earnings and revenue surprises of +24.42% and +3.79%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqANIP, TWST
- ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlookSeeking Alpha
- ANI Pharmaceuticals Reports Third Quarter 2026 Financial ResultsPRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended…GlobeNewswire
- REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease BusinessPRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ)…GlobeNewswire
- ANI Offers $560 Mln To Acquire Egetis, Expand Rare Disease Business(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) on Thursday announced a recommended cash offer to acquire Egetis Therapeutics for approximately SEK5.6 billion, or $560 million, including outstanding…NasdaqANIP, WSO.B
- ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease BusinessPRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ)…GlobeNewswire
- ANI Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha
- ANI Pharmaceuticals to Present at Upcoming November Investor ConferencesPRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with…GlobeNewswire
- ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ETPRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results…GlobeNewswire
- ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules In 20, 30 And 60 Mg(RTTNews) - Monday, ANI Pharmaceuticals, Inc. (ANIP) announced the launch of Duloxetine Delayed-Release Capsules in 20, 30 and 60 mg, the generic version of the reference listed drug (RLD) Cymbalta.NasdaqANIP, BRK.A
- ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release CapsulesPRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg.…GlobeNewswire
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarFinding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.NasdaqANIP, REGN
- ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study(RTTNews) - ANI Pharmaceuticals (ANIP) announced positive results from its Phase 4 SYNCHRONICITY trial evaluating the Fluocinolone Acetonide Intravitreal Implant in patients with chronic…NasdaqANIP, ET
- ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual MeetingANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that both 6-month and 24-month data from SYNCHRONICITY, its Phase 4, open-label, single-arm clinical trial of…GlobeNewswire
- How to Find Strong Medical Stocks Slated for Positive Earnings SurprisesFinding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.NasdaqSOLV, ANIP
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) - Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across…NasdaqABBV, ABEO, AMRX, ANIP
- ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock DownEsperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.NasdaqRDY, ANIP